A 3907
Alternative Names: A-3907; IPN-60250Latest Information Update: 28 Dec 2024
At a glance
- Originator Albireo Pharma
- Developer Albireo Pharma; Ipsen
- Class Anti-inflammatories; Antifibrotics; Hepatoprotectants
- Mechanism of Action Sodium-bile acid cotransporter inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Primary sclerosing cholangitis
- No development reported Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Primary biliary cirrhosis
Most Recent Events
- 28 Dec 2024 No recent reports of development identified for preclinical development in Non-alcoholic-fatty-liver-disease in USA (PO)
- 28 Dec 2024 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in USA (PO)
- 28 Apr 2024 No recent reports of development identified for phase-I development in Primary-biliary-cirrhosis(In volunteers) in USA (PO)